Dept. of Medical Genetics, Medical University of Silesia, Sosnowiec, Poland.
J Neuropsychiatry Clin Neurosci. 2013 Winter;25(1):88-94. doi: 10.1176/appi.neuropsych.11100234.
The brain-derived neurotrophic factor (BDNF) is one of the candidate genes for schizophrenia. There is evidence that val66met polymorphism may be involved in the pathophysiology of schizophrenia. The authors genotyped val66met (rs6265) polymorphism of the BDNF gene in 208 inpatients with paranoid schizophrenia and 254 control subjects in a Polish population. There was no association between val66met polymorphism and development of paranoid schizophrenia in either men or women. However, an association was found between this polymorphism and age at onset and psychopathology of paranoid schizophrenia. Men with the val/met genotype had an earlier age at onset, and the val/val genotype predisposed to more severe symptoms, particularly on the General Psychopathology Scale of the Positive and Negative Symptoms Scale (PANSS-G). The analysis of PANSS single items has shown that patients with the val/met genotype had higher scores on a hallucinatory behavior item than those with other genotypes.
脑源性神经营养因子（BDNF）是精神分裂症的候选基因之一。有证据表明，val66met 多态性可能与精神分裂症的病理生理学有关。作者在波兰人群中对 208 例偏执型精神分裂症住院患者和 254 名对照进行了 BDNF 基因 val66met(rs6265)多态性的基因分型。在男性或女性中，val66met 多态性与偏执型精神分裂症的发病无关。然而，这种多态性与偏执型精神分裂症的发病年龄和精神病理学之间存在关联。携带 val/met 基因型的男性发病年龄更早，而 val/val 基因型更容易出现更严重的症状，特别是在阳性和阴性症状量表（PANSS-G）的一般精神病学量表上。对 PANSS 单项的分析表明，携带 val/met 基因型的患者在幻觉行为项目上的得分高于其他基因型的患者。
